[go: up one dir, main page]

WO2009072749A3 - Biomarqueur pour le diagnostic de l'asthme et agent thérapeutique de l'expression de la protéine de liaison de la vitamine d pour lutter contre l'asthme - Google Patents

Biomarqueur pour le diagnostic de l'asthme et agent thérapeutique de l'expression de la protéine de liaison de la vitamine d pour lutter contre l'asthme Download PDF

Info

Publication number
WO2009072749A3
WO2009072749A3 PCT/KR2008/006539 KR2008006539W WO2009072749A3 WO 2009072749 A3 WO2009072749 A3 WO 2009072749A3 KR 2008006539 W KR2008006539 W KR 2008006539W WO 2009072749 A3 WO2009072749 A3 WO 2009072749A3
Authority
WO
WIPO (PCT)
Prior art keywords
asthma
dbp
biomarker
vitamin
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/006539
Other languages
English (en)
Other versions
WO2009072749A2 (fr
Inventor
Choon-Sik Park
Taiyoun Rhim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academy Cooperation Foundation of Soonchunhyang University
Original Assignee
Industry Academy Cooperation Foundation of Soonchunhyang University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academy Cooperation Foundation of Soonchunhyang University filed Critical Industry Academy Cooperation Foundation of Soonchunhyang University
Publication of WO2009072749A2 publication Critical patent/WO2009072749A2/fr
Publication of WO2009072749A3 publication Critical patent/WO2009072749A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Selon cette invention, on a comparé des profils de protéines BALF d'un patient atteint d'asthme bronchique et de sujets normaux en bonne santé par électrophorèse bidimensionnelle (2D), puis on a choisi la protéine de liaison de la vitamine D (DBP) parmi des spots protéiques qui s'exprimaient différemment dans les protéines BALF du patient atteint d'asthme, et on a validé les différentes expressions dans un modèle de souris sensibilisé à l'ovalbumine. Dans un modèle de souris sensibilisé/provoqué à l'OVA, le traitement par un anticorps anti-DBP a entraîné une réduction significative de l'hyperexcitabilité bronchique, du nombre de cellules inflammatoires et des productions de cytokines, validant la relation entre l'asthme et la DBP. Il s'avère également que la provocation des souris à la DBP a généré des aspects pathologiques typiques de l'asthme allergique. L'invention concerne également la relation entre le degré d'expression de la protéine DBP et l'asthme, et un agent thérapeutique de l'asthme utilisant un biomarqueur pour l'asthme, des anticorps ou des antisens de DBP.
PCT/KR2008/006539 2007-12-03 2008-11-06 Biomarqueur pour le diagnostic de l'asthme et agent thérapeutique de l'expression de la protéine de liaison de la vitamine d pour lutter contre l'asthme Ceased WO2009072749A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070124476A KR100953821B1 (ko) 2007-12-03 2007-12-03 비타민 ｄ 결합 단백질을 이용한 천식 진단 마커 및 천식치료제
KR10-2007-0124476 2007-12-03

Publications (2)

Publication Number Publication Date
WO2009072749A2 WO2009072749A2 (fr) 2009-06-11
WO2009072749A3 true WO2009072749A3 (fr) 2009-07-23

Family

ID=40718315

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/006539 Ceased WO2009072749A2 (fr) 2007-12-03 2008-11-06 Biomarqueur pour le diagnostic de l'asthme et agent thérapeutique de l'expression de la protéine de liaison de la vitamine d pour lutter contre l'asthme

Country Status (2)

Country Link
KR (1) KR100953821B1 (fr)
WO (1) WO2009072749A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027308A1 (fr) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Nouveaux marqueurs tumoraux
EP2819749A4 (fr) * 2012-03-01 2016-03-02 Univ Columbia Biomarqueurs associés à l'autisme et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013629A2 (fr) * 2002-07-29 2004-02-12 Novartis Ag Composes organiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013629A2 (fr) * 2002-07-29 2004-02-12 Novartis Ag Composes organiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 28 October 2007 (2007-10-28), "Homo sapiens group-specific component (vitamin D binding protein)", Database accession no. NM_000583 *
ISABELLE NOEL-GEORIS ET AL.: "Database of bronchoalveolar lavage fluid proteins.", JOURNAL OF CHROMATOGRAPHY B., vol. 771, no. 1-2, May 2002 (2002-05-01), pages 221 - 236 *
MATTHIAS WJST: "Variants in the vitamin D receptor gene and asthma.", BMC GENETICS., vol. 6, January 2005 (2005-01-01), pages 2. *
R. WATTIEZ ET AL.: "Proteomics of bronchoalveolar lavage fluid.", JOURNAL OF CHROMATOGRAPHY B., vol. 815, no. 1-2, February 2005 (2005-02-01), pages 169 - 178 *

Also Published As

Publication number Publication date
WO2009072749A2 (fr) 2009-06-11
KR20090057758A (ko) 2009-06-08
KR100953821B1 (ko) 2010-04-21

Similar Documents

Publication Publication Date Title
WO2006105252A3 (fr) Diagnostic de la bronchopneumopathie chronique obstructive, et suivi de la therapie associee par analyse de l'expression de cellules sanguines
WO2008065378A3 (fr) Composés
Cavelti-Weder et al. Inhibition of IL-1β improves fatigue in type 2 diabetes
WO2007143098A3 (fr) Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
WO2007143090A3 (fr) Protéines de liaison au facteur de croissance des cellules hépatiques (hgf)
WO2010145796A3 (fr) Biomarqueurs et procédés pour déterminer l'efficacité d'anticorps anti-egfr dans une thérapie d'un cancer
WO2007074193A3 (fr) Procede d'analyse d'expression differentielle dans le cancer colorectal
WO2007147600A3 (fr) Expression différentielle de la cytokine dans les cancers chez l'homme
WO2010025369A3 (fr) Utilisations de cytokines des familles il-22, il-17, et il-1 dans les maladies auto-immunes
WO2008139207A3 (fr) Agents d'imagerie de peptide
WO2008088854A3 (fr) Marqueurs génétiques pour la prédiction de sensibilité à une polythérapie
WO2012054732A3 (fr) Tests du cancer du poumon
WO2011117366A3 (fr) Gènes et combinaisons de gènes prédictifs d'une réponse précoce ou d'une non-réponse de sujets souffrant d'une maladie inflammatoire à des médicaments ciblant les cytokines (cytd)
WO2013071012A3 (fr) Traitement stratégique personnalisé contre le cancer
WO2009072749A3 (fr) Biomarqueur pour le diagnostic de l'asthme et agent thérapeutique de l'expression de la protéine de liaison de la vitamine d pour lutter contre l'asthme
WO2009108390A3 (fr) Méthode permettant d'atteindre des concentrations plasmiques désirées du facteur de croissance gliale 2
WO2010116003A3 (fr) Méthode permettant de prédire la réponse à une pharmacothérapie ciblée de patients atteints d'un cancer du poumon du type non à petites cellules
WO2012131092A3 (fr) Procédé et kits de prédiction d'une réponse/absence de réponse au traitement, au moyen d'un anticorps anti-egfr chez des patients atteints d'un cancer colorectal à tous les stades de l'uicc
WO2005083083A3 (fr) Matieres et procedes destines au traitement de maladies allergiques
WO2008106076A3 (fr) Procédés pour surveiller la progression de la maladie d'alzheimer en utilisant des marqueurs csf à partir d'échantillons longitudinaux
EP2123299A4 (fr) Agent therapeutique pour maladie pulmonaire interstitielle comportant un anticorps anti-hmgb-1
Brooks et al. C38 BIOMARKERS OF ACUTE AND CHRONIC INFLAMMATION: Clinical Findings In Patients With Co-Morbid Conditions Of Asthma And Diabetes
WO2008119858A8 (fr) Méthode in vitro non invasive permettant de détecter un carcinome transitionnel de la vessie
Fischer et al. LUNG DISEASE SEVERITY, CHRONIC INFLAMMATION, IRON DEFICIENCY AND ERYTHROPOETIC RESPONSE IN ADULTS WITH CYSTIC FIBROSIS: 384
MI et al. The clinical significance of TNFR1 and TNFR2 in early diabetic nephropathy of type 2 diabetes

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08856138

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08856138

Country of ref document: EP

Kind code of ref document: A2